1. Development of a Next Generation Concurrent Framework for the ATLAS Experiment. Issue 7 (December 2015) Authors: Calafiura, P.; Lampl, W.; Leggett, C.; Malon, D.; Stewart, G.; Wynne, B. Journal: Journal of physics Issue: Volume 664:Issue 7(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Divertorlets concept for low-recycling fusion reactor divertor: experimental, analytical and numerical verification. (1st August 2022) Authors: Saenz, F.; Sun, Z.; Fisher, A.E.; Wynne, B.; Kolemen, E. Journal: Nuclear fusion Issue: Volume 62:Number 8(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor–Naive Patients. Issue 5 (September 2014) Authors: Curtis, L.; Nichols, G.; Stainsby, C.; Lim, J.; Aylott, A.; Wynne, B.; Clark, A.; Bloch, M; Maechler, G.; Martin-Carpenter, L..; Raffi, F.; Min, S. Journal: HIV clinical trials Issue: Volume 15:Issue 5(2014) Page Start: 199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies. Issue 2 (February 2020) Authors: Cahn, P.; Madero, J. Sierra; Arribas, J.; Antinori, A.; Ortiz, R.; Clarke, A.; Hung, C.; Rockstroh, J.; Girard, P.; Sievers, J.; Man, C.; Urbaityte, R.; Underwood, M.; Tenorio, A.; Pappa, K.; Wynne, B.; Gartland, M.; Aboud, M.; van Wyk, J.; Smith, K. Journal: Journal of infection and public health Issue: Volume 13:Issue 2(2020) Page Start: 349 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Switching to DTG/3TC fixed-dose combination (FDC) Is non-inferior to continuing a TAF-based regimen in maintaining virologic suppression through 48 weeks (TANGO Study). Issue 2 (February 2020) Authors: Van Wyk, J.; Ajana, F.; Bisshop, F.; De Wit, S.; Osiyemi, Y.; Portilla, J.; Routy, J.; Wyen, C.; Ait-Khaled, M.; Nascimento, M.; Pappa, K.; Wang, R.; Wright, J.; Tenorio, A.; Wynne, B.; Aboud, M.; Gartland, M.; Smith, K.; El-Bahy, Y. Journal: Journal of infection and public health Issue: Volume 13:Issue 2(2020) Page Start: 349 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies. Issue 1 (January 2019) Authors: Orkin, C.; Porteiro, N.; Berhe, M.; Dretler, R.; Viciana, P.; Tseng, Y.; Oprea, C.; Johnson, M.; Kulagin, V.; Man, C.; Sievers, J.; Currie, A.; Underwood, M.; Tenorio, A.; Pappa, K.; Wynne, B.; Aboud, M.; Smith, K.; Gartland, M.; Steinhart, C. Journal: Journal of infection and public health Issue: Volume 12:Issue 1(2019) Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗